论文部分内容阅读
目的:对比分析HER2阴性乳腺癌4、6周期(1个周期就是1个疗程,时间为21 d)新辅助化疗疗效,以及相关分子标志物:ER、PR、Ki-67的表达水平对HER2阴性乳腺癌化疗效果的影响。方法:随机选择深圳市二人民医院在2014年10月至2015年10月收治的HER2阴性乳腺癌患者100例。其中50例实施4周期的新辅助化疗的治疗,另50例实施6周期的新辅助化疗。使用统计学分析的方法对比分析乳腺癌患者在实施4周期以及6周期后的新辅助化疗的治疗效果。另需要对比两组患者相关分子标志物:ER、PR、Ki-67的表达变化水平对HER2阴性乳腺癌化疗疗效的影响。结果:(1)4周期组和6周期组新辅助化疗的总有效率无差异。(2)在新辅助化疗后的ER或PR方面,阴性患者4周期和6周期的治疗有效率差异无统计学意义(P>0.05);阳性4周期和6周期有效率无差异。(3)在Ki-67的表达方面,Ki-67阴性患者4周期和6周期有效率无差异。Ki-67阳性患者,4周期治疗有效率为92%,6周期有效率为57%,差异具有统计学意义(P<0.05)。结论:(1)HER2阴性乳腺癌患者,4周期或6周期新辅助化疗,均能够取得较好的临床治疗效果。(2)在新辅助化疗后的ER或PR方面,无论是阴性还是阳性表达患者,在经过4周期或6周期的新辅助化疗后,其临床治疗效果并无显著差异。(3)在Ki-67表达方面,阳性患者的治疗效果明显高于阴性患者。
OBJECTIVE: To compare and analyze the efficacy of neoadjuvant chemotherapy in HER2-negative breast cancer patients treated with neoadjuvant chemotherapy for 4 and 6 cycles (1 cycle for 21 days) and the related molecular markers ER, PR and Ki-67 were negative for HER2 Effect of Chemotherapy in Breast Cancer. Methods: 100 cases of HER2-negative breast cancer were randomly selected from Shenzhen Second People’s Hospital from October 2014 to October 2015. Among them, 50 cases were treated with 4 cycles of neoadjuvant chemotherapy and the other 50 cases were given 6 cycles of neoadjuvant chemotherapy. The statistical analysis was used to compare the therapeutic effect of neoadjuvant chemotherapy in breast cancer patients after 4 cycles and 6 cycles. Another need to compare the two groups of patients related molecular markers: ER, PR, Ki-67 expression levels of HER2-negative breast cancer chemotherapy effect. Results: (1) There was no difference in the total effective rate of neoadjuvant chemotherapy between 4-cycle group and 6-cycle group. (2) In the ER or PR after neoadjuvant chemotherapy, there was no significant difference between the 4 and 6 cycles in negative patients (P> 0.05). There was no difference in the positive 4 and 6 cycles. (3) In the expression of Ki-67, Ki-67-negative patients 4 cycles and 6 cycles no difference in efficiency. Ki-67-positive patients, 4 cycles of treatment efficiency was 92%, 6-cycle efficiency was 57%, the difference was statistically significant (P <0.05). Conclusions: (1) Neoadjuvant chemotherapy in patients with HER2 negative breast cancer, 4 cycles or 6 cycles, can achieve better clinical treatment effect. (2) There is no significant difference in the clinical efficacy of neoadjuvant chemotherapy after neoadjuvant chemotherapy in patients with either negative or positive expression of ER or PR after neoadjuvant chemotherapy. (3) In Ki-67 expression, the therapeutic effect of positive patients was significantly higher than negative patients.